Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00828555
Other study ID # Pro00011038
Secondary ID
Status Completed
Phase N/A
First received January 22, 2009
Last updated October 15, 2012
Start date November 2008
Est. completion date February 2012

Study information

Verified date September 2012
Source Duke University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

PURPOSE To develop, implement, and evaluate the effectiveness of a program designed to assist community Ob/Gyns in vaccinating adolescent and adult women against vaccine-preventable diseases.

SPECIFIC AIMS

1. Determine the feasibility of implementing a successful vaccination program for adolescent and adult women in Ob/Gyn offices by direct assessment of medical personnel & office staff on their:

- Attitudes towards vaccination of women against preventable diseases

- Perceived barriers to implementing a program to vaccinate women in their offices

- Ideas on how to overcome barriers to successful program implementation

- Current vaccination practices and office-specific administrative processes

2. Design & implement a program for Ob/Gyns to vaccinate women against human papillomavirus, influenza, & pertussis

3. Determine the effectiveness of the vaccination program based on

- Pre- and post-program vaccination rates

- Program satisfaction amongst Ob/Gyn providers and office staff

- Willingness to continue and possibly extend the program to additional vaccines

4. Quantify the level of support and resources needed to develop and implement the vaccination program


Recruitment information / eligibility

Status Completed
Enrollment 3988
Est. completion date February 2012
Est. primary completion date April 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 12 Years to 26 Years
Eligibility Inclusion Criteria:

- 4-5 community Ob/Gyn practices

Study Design

N/A


Intervention

Other:
Vaccination Program
Design & implement a program for Ob/Gyns to vaccinate women against human papillomavirus, influenza, & pertussis

Locations

Country Name City State
United States Westside OBGYN Burlington North Carolina
United States DWHA Durham North Carolina
United States Atrium OBGYN Raleigh North Carolina
United States Blue Ridge OBGYN Raleigh North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Duke University Centers for Disease Control and Prevention

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Implementation and measurement of a health services intervention in community or private Ob/Gyn practices to improve the delivery of standard clinical care to vaccinate women against human papillomavirus, influenza, & pertussis. Full-scale program implementation will cover a 12 month period, tentatively planned to begin in April 2009. No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04056728 - A Phase IV Study to Assess the Safety of EupentaTM Inj Phase 4
Completed NCT02453048 - Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine Phase 1
Completed NCT01917357 - A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject Phase 3
Completed NCT02526394 - Pertussis and Meningitis C Concomitant Vaccination in Adolescents Phase 4
Completed NCT01689324 - Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescents Phase 1/Phase 2
Completed NCT01214889 - Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants. Phase 3
Completed NCT00804284 - Database Surveillance Safety Study of PENTACEL® Vaccine N/A
Completed NCT00514709 - Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants Phase 3
Completed NCT00534833 - Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™ Phase 3
Completed NCT00524732 - Assessment of the Reactogenicity of ADACEL® (TdcP Vaccine) in Children and Adolescents 7 to 19 Years of Age N/A
Completed NCT00772369 - Retrospective Survey of Safety of Fourth Dose Pentacel® in Children Phase 4
Completed NCT01457495 - Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly Phase 2
Completed NCT01267058 - Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults Phase 3
Completed NCT00004800 - Phase III Randomized, Double-Blind, Placebo-Controlled Study of Acellular and Whole-Cell Pertussis Vaccines Phase 3
Completed NCT02858440 - A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia Phase 3
Recruiting NCT04023929 - Sources of COmplement in Meningococcal and Pertussis Serum Bactericidal Antibody Assays
Completed NCT02946190 - The PertADO Geneva Trial Phase 2
Completed NCT03541499 - Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Healthy Adults Phase 2
Completed NCT02587520 - Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects Phase 1/Phase 2
Completed NCT04589312 - Maternal Pertussis Wholecell Responses Phase 2